ElastaGlo (Elastin Peptides)

ElastaGlo contains elastin peptides that may inhibit elastase enzyme activity, potentially supporting extracellular matrix integrity. The bioactive peptides include proline-rich sequences that could theoretically influence skin elasticity pathways.

Origin & History

ElastaGlo is a branded form of elastin peptides derived from animal tissues, specifically bovine arteries or deep-sea bonito fish heart arterial tissue. The production involves alkali extraction with 0.1 M NaOH followed by enzymatic hydrolysis using proteases like Alcalase® 2.4L at 55°C for 3-24 hours to generate low-molecular-weight peptides rich in glycine, alanine, and valine.

Historical & Cultural Context

No evidence of traditional medicinal use for ElastaGlo or elastin peptides in historical healing systems such as Ayurveda or Traditional Chinese Medicine was found. The ingredient represents a modern biotechnological approach to extracting peptides from animal sources without documented cultural or historical precedent.

Health Benefits

• May inhibit elastase activity based on in-vitro studies (preliminary evidence only)
• Potential support for extracellular matrix integrity (theoretical, no clinical data)
• Could influence skin elasticity pathways (mechanistic hypothesis, no human trials)
• May provide bioactive peptides like Pro-Gly found in elastin sources (compositional data only)
• Possible anti-aging applications (speculative, no clinical validation)

How It Works

ElastaGlo elastin peptides may inhibit elastase enzyme activity through competitive binding mechanisms, potentially preserving existing elastin fibers in the extracellular matrix. The proline-rich peptide sequences could theoretically stimulate fibroblast activity and influence collagen-elastin cross-linking pathways. However, these mechanisms are based on in-vitro studies and mechanistic hypotheses rather than confirmed human data.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on ElastaGlo or branded elastin peptides were identified in the available research. Current studies are limited to production methods, extraction techniques, and in-vitro elastase inhibitory activity of generic elastin hydrolysates from bovine sources, with no PubMed PMIDs for human trials provided.

Clinical Summary

Current evidence for ElastaGlo is limited to preliminary in-vitro studies showing potential elastase inhibition. No published human clinical trials have evaluated its effects on skin elasticity or other health outcomes. The existing research consists primarily of mechanistic studies and theoretical frameworks rather than controlled human interventions. More robust clinical evidence is needed to establish efficacy and optimal dosing protocols.

Nutritional Profile

ElastaGlo (Elastin Peptides) is a peptide-based ingredient derived from elastin protein sources (typically bovine or marine origin). Primary macronutrient contribution is protein/peptide content, estimated at 85-95% protein by dry weight, with negligible fat and carbohydrate content. Caloric contribution is approximately 3.4-3.8 kcal/g. Bioactive compounds include low-molecular-weight elastin-derived peptides, predominantly in the 500-2000 Da molecular weight range, which theoretically favors intestinal absorption over intact proteins. Key peptide sequences identified in elastin hydrolysates include Pro-Gly (proline-glycine), Val-Gly-Val-Ala-Pro-Gly (VGVAPG hexapeptide), and other proline-rich dipeptides and tripeptides. Amino acid composition reflects elastin's characteristic profile: glycine (~30-33% of total amino acids), proline (~10-13%), valine (~10-12%), alanine (~20-22%), and desmosine/isodesmosine crosslink residues at trace levels (<1%). Micronutrient content is minimal and not a primary contribution of this ingredient. No dietary fiber content. Bioavailability of elastin peptides is considered moderate; the high proline and glycine content may limit conventional peptide transport efficiency, though small di- and tripeptides are absorbed via PepT1 transporter mechanisms. No standardized clinical bioavailability data specific to ElastaGlo is currently published.

Preparation & Dosage

No clinically studied dosage ranges for ElastaGlo or elastin peptides have been established due to the absence of human trials. The available research only describes production methods yielding lyophilized powders without specified standardization or therapeutic dosing guidelines. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Collagen peptides, Vitamin C, Hyaluronic acid, Biotin, Zinc

Safety & Interactions

Safety data for ElastaGlo elastin peptides is limited due to lack of comprehensive human studies. As a protein-derived supplement, it may cause digestive upset in sensitive individuals or those with protein allergies. No specific drug interactions have been documented, but individuals taking anticoagulant medications should consult healthcare providers due to potential peptide interactions. Safety during pregnancy and breastfeeding has not been established.